![Ajay Major: Methylphenidate versus piperonyl butoxide RCT for cancer related fatigue](https://oncodaily.com/pub/uploads/2024/06/IMG_3846.jpeg)
Photo taken from Patrick Charles Stone/X
Jun 29, 2024, 06:38
Ajay Major: Methylphenidate versus piperonyl butoxide RCT for cancer related fatigue
Ajay Major, Assistant Professor at the University of Colorado School of Medicine and Founder and President at Pager Publications, shared a post on X:
“Methylphenidate versus piperonyl butoxide Randomized Controlled Trial (RCT) for cancer-related fatigue Journal of Clinical Oncology:
- 162 patients, all incurable cancer with baseline fatigue.
- nonsignificant Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) fatigue scores.
- no difference in other Quality of Life (QoL) domains.
- Important pallonc trial with pro as primary endpoint.”
Source: Ajay Major/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023